Alzeca Biosciences

Alzeca Biosciences Focuses on Developing Innovative MRI Contrast Agents Specifically for the Early Diagnosis of Neurodegenerative Diseases, Including Alzheimer's Disease. The nanoparticle molecules used in its patented MRI contrast agents can specifically bind to abnormal pathogenic proteins in the brain, allowing for early imaging of the accumulation of these pathogenic proteins in the brain before cognitive symptoms appear in patients, thus enabling early diagnosis. Therefore, the company's patented contrast agent aims to let people know in advance whether they have developed dementia, such as Alzheimer's disease.